

## Supplemental Figure Legends

***Figure S1: Mutation pattern remains unchanged upon miR-155 over-expression in vivo.***

Mutants were isolated, PCR amplified, sequenced, and analyzed for transition/transversion or insertion/deletion mutations. Results are reported as a percentage of total mutants sequenced.

***Figure S2: Validation of DSB repair assays***

Matched pair control cell lines with known DSB repair phenotypes: xrs6 and xrs6 + Ku80, DLD1 and DLD1 BRCA2 knockout, PEO1 and PEO1 C4-2 BRCA2 complemented, were analyzed for (A) NHEJ pathway activity and (B) HR pathway activity using luciferase based DSB reporters. (C) Western blot analysis of FOXO3a following pre-miR-155 transfection and confirmation of siRNA targets. (D) Effect on miR-155, siBRCA2, siRAD51 and siXRCC4 on the U2OS DR-GFP assay for HR. (E) Mutagenic end-joining analysis using the U2OS DR-EJ cells. MMEJ analysis by host cell reactivation of pEJ2 comparing (F) xrs6 cells to xrs6 + Ku80, (G) 155 KI MEFs to wild type controls, and (H) BICKO MEFs.

***Figure S3: Confirmation of polymerase delta mRNA down-regulation***

qRT-PCR analysis of polymerase delta subunit mRNA levels in AV16 155 and AV16 NTC cells

***Figure S4: NHEJ activity is unchanged upon FOXO3a knockdown in AV16 cells***

NHEJ pathway activity in AV16 cells after siRNA knockdown of FOXO3a

Figure S1




Figure S2











Figure S3




Figure S4

